Pharmaceutical Companies à Vancouver, BC avec horaires d’ouverture, site web

Trouvez des données précises sur les meilleures entreprises de la catégorie Pharmaceutical Companies à Vancouver. Voir les avis et les coordonnées de chaque entreprise, y compris numéro de téléphone, adresse, heures d'ouverture, promotions et d'autres informations.
Affichage des résultats: 1 - 19 sur 19

Résultats à proximité dans la catégorie Pharmaceutical Companies à Vancouver

Verity Pharmaceuticals

Fermé maintenant

595 Burrard St, Suite 2600, Vancouver, V7X 1L3

(215) 550-6077

Pharmaceutical company

InMed Pharmaceuticals

Fermé maintenant

885 W Georgia St #1445, DOWNTOWN, Vancouver, V6C 3E8

(604) 669-7207

InMed Pharmaceuticals is a clinical stage biopharmaceutical company that specializes in developing therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed is utilizing its proprietary "Intelligent Cannabinoid Drug Design Platform" to identify new bioactive compounds within the cannabis plant that interact with certain genes responsible for specific diseases. These newly discovered drug candidates are developed from cannabinoids and other botanical sources significantly reduce side effects while optimizing therapeutic benefits. Our proprietary platform technology, product pipeline, and accelerated drug discovery/development pathway are the fundamental value drivers of the Company.

Shackelford Pharma

Fermé maintenant

700 W Georgia Street, Vancouver, V7Y 1B3

Pharmaceutical company

Syreon Corp.

Fermé maintenant

220—1401 West 8 th Ave, FAIRVIEW, Vancouver, V6H 1C9

(604) 676-5900

proprietaries, Drugs & Sundries, Pharmaceutical company, Wholesale Trade Nondurable Goods, Drugs, Wholesale Trade, pharmaceutical products, sundries

Aquinox Pharmaceuticals Inc

Fermé maintenant

887 Great Northern Way #450, Vancouver, V5T 4T5

604.629.9223

We are a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Our lead product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. Having successfully completed multiple preclinical studies and three clinical trials with AQX-1125, we are now advancing through Phase 2 development. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1.